drugset / Trial / NCT04173793
A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety and efficacy of AK102 in patients with heterozygous familial hypercholesterolemia (HeFH).The primary objective of this study is to evaluate the efficacy of AK102 in patients with HeFH.
Timeline
- Start
- 2019-11-18
- Primary completion
- 2022-09-26
- Completion
- 2022-09-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK102 | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | AK102 | Monoclonal antibody | 300 mg | Subcutaneous |
| Subject | AK102 | Monoclonal antibody | 450 mg | Subcutaneous |
| Background | Ezetimibe | Unknown | — | — |